ClinicalTrials.gg
CompletedNCT03661320Updated Sep 10, 2026

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

A Phase 3 interventional study of Nivolumab and Gemcitabine in Urinary Bladder Neoplasms and Muscle-Invasive Bladder Cancer, sponsored by Bristol-Myers Squibb. Completed at 172 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
855
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing nivolumab in Urinary Bladder Neoplasms — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Urinary Bladder Neoplasms.

Enrollment
2nd of 25
855 · median 76
Started
2018
with 5 others
Phase 3
4 of 25
none open now
Registered
13th of 25
by date
Lead sponsor
5 of 25
Bristol-Myers Squibb

Among the 25 studies testing nivolumab in Urinary Bladder Neoplasms, this one is the 2nd largest by enrollment, is one of 6 that started in 2018, is one of 4 in phase 3, and was the 13th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

3 of the 25 studies testing nivolumab in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing nivolumab in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).

03

Conditions studied

  • Urinary Bladder Neoplasms
  • Muscle-Invasive Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be deemed eligible for Radial Cystectomy (RC) by his/her oncologist and/or urologist, and must agree to undergo Radial Cystectomy (RC) after completion of therapy.
  • (ECOG) Performance Status 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of positive lymph node(s) (LN) (≥ 10 mm in short axis) or bladder cancer
  • Prior systemic therapy, radiation therapy, or surgery for bladder cancer other than trans urethral resection of bladder tumor (TURBT) or is also not permitted
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
855 participants (actual)

Study arms

  • Active comparator
    Arm A: Gemcitabine/Cisplatin (GC) Chemotherapy

    Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    Arm B: Nivolumab + GC Chemotherapy

    Biological: Nivolumab · Drug: Gemcitabine · Drug: Cisplatin

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • Specified dose on specified days

    Also known as: Chemotherapy

  • Specified dose on specified days

    Also known as: Chemotherapy

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) rate, in all randomized participants

    Arm B vs. Arm A

    Time frame: Approximately 43 months

  2. Event-Free Survival (EFS), in all randomized participants

    Arm B vs. Arm A

    Time frame: Approximately 36 months

Secondary outcomes

  1. Overall Survival (OS) in all randomized participants

    Arm B vs. Arm A

    Time frame: Approximately 60 months

  2. Incidence of Adverse Events (AE) in participants who received at least one treatment dose

    Time frame: Approximately 60 months

  3. Incidence of Serious Adverse Events (SAE) in participants who received at least one treatment dose

    Time frame: Approximately 60 months

  4. Incidence of deaths in participants who received at least one treatment dose

    Time frame: Approximately 60 months

  5. Incidence of laboratory abnormalities in participants who received at least one treatment dose

    Time frame: Approximately 60 months

  6. pCR rate, descriptively in all concurrently randomized participants

    Arm C vs. Arm B and Arm A

    Time frame: Approximately 43 months

  7. EFS, descriptively in all concurrently randomized participants

    Arm C vs. Arm B and Arm A

    Time frame: Approximately 36 months

  8. OS, descriptively in all concurrently randomized participants

    Arm C vs. Arm B and Arm A

    Time frame: Approximately 60 months

07

Study locations

172 sites
  • Local Institution - 0022
    Tucson, Arizona 85711, United States
  • UC Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
  • Local Institution - 0021
    Littleton, Colorado 80120-4413, United States
  • Local Institution - 0036
    Pensacola, Florida 32503, United States
  • Local Institution - 0004
    Tampa, Florida 33612, United States
  • Local Institution - 0144
    Atlanta, Georgia 30342, United States
  • Local Institution - 0005
    Chicago, Illinois 60637, United States
  • Local Institution - 0006
    Peoria, Illinois 61615, United States
  • Local Institution - 0181
    Columbia, Maryland 21044, United States
  • Local Institution - 0009
    Boston, Massachusetts 02114, United States
  • Local Institution - 0166
    Boston, Massachusetts 02215, United States
  • Local Institution - 0209
    Boston, Massachusetts 02215, United States
  • Local Institution - 0025
    Minneapolis, Minnesota 55404, United States
  • Local Institution - 0129
    Minneapolis, Minnesota 55455, United States
  • Local Institution - 0183
    Omaha, Nebraska 68130, United States
  • Local Institution - 0001
    Omaha, Nebraska 68198-6840, United States
  • Local Institution - 0024
    Las Vegas, Nevada 89169, United States
  • Local Institution - 0029
    Albany, New York 12208, United States
  • Local Institution - 0069
    Lake Success, New York 11042, United States
  • Local Institution - 0047
    New York, New York 10065, United States
  • Local Institution - 0191
    Cleveland, Ohio 44195, United States
  • Local Institution - 0028
    Tigard, Oregon 97223, United States
  • Local Institution - 0189
    Charleston, South Carolina 29425, United States
  • Local Institution - 0007
    Nashville, Tennessee 37232, United States
  • Local Institution - 0030
    Austin, Texas 78731, United States
  • Local Institution - 0023
    Norfolk, Virginia 23502, United States
  • Local Institution - 0051
    Capital Federal, Buenos Aires 1426, Argentina
  • Local Institution - 0049
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1280, Argentina
  • Local Institution - 0151
    Ciudad Autonoma Buenos Aires, Distrito Federal 1118, Argentina
  • Local Institution - 0131
    Garran, Australian Capital Territory 2605, Australia
  • Local Institution - 0130
    Kingswood, New South Wales 2747, Australia
  • Local Institution - 0157
    Macquarie University, New South Wales 2109, Australia
  • Local Institution - 0043
    St Leonards, New South Wales 2065, Australia
  • Local Institution - 0143
    North Adelaide, South Australia 5006, Australia
  • Local Institution - 0037
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0038
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0090
    Klagenfurt, 9020, Austria
  • Local Institution - 0091
    Krems, 3500, Austria
  • Local Institution - 0011
    Linz, 4020, Austria
  • Local Institution - 0012
    Vienna, 1090, Austria
  • Local Institution - 0060
    Brussels, 1200, Belgium
  • Local Institution - 0063
    Ghent, 9000, Belgium
  • Local Institution - 0062
    Wilrijk, 2610, Belgium
  • Local Institution - 0094
    Fortaleza, Ceará 60130-241, Brazil
  • Local Institution - 0099
    Ipatinga, Minas Gerais 35160-158, Brazil
  • Local Institution - 0092
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0212
    Porto Alegre, Rio Grande do Sul 90035-001, Brazil
  • Local Institution - 0097
    Porto Alegre, Rio Grande do Sul 90610000, Brazil
  • Local Institution - 0098
    Barretos, São Paulo 14780-070, Brazil
  • Local Institution - 0095
    Jaú, São Paulo 17210-080, Brazil
  • Local Institution - 0093
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • Local Institution - 0164
    Rio de Janeiro, 20231-050, Brazil
  • Local Institution - 0214
    São Paulo, 01221-020, Brazil
  • Local Institution - 0159
    Kelowna, British Columbia V1Y 5L3, Canada
  • Local Institution - 0182
    North York, Ontario M2K 1E1, Canada
  • Local Institution - 0192
    Chicoutimi, Quebec G7H 5H6, Canada
  • Local Institution - 0190
    Montreal, Quebec H3T 1M5, Canada
  • Local Institution - 0053
    Santiago, Santiago Metropolitan 8330024, Chile
  • Local Institution - 0052
    Santiago, Santiago Metropolitan 8380456, Chile
  • Local Institution - 0210
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0054
    Santiago, Santiago Metropolitan, Chile
  • Local Institution - 0201
    Colombia, Bogota D.C. 0, Colombia
  • Local Institution - 0104
    Bucaramanga, 681004, Colombia
  • Local Institution - 0103
    Montería, 230003, Colombia
  • Local Institution - 0148
    Helsinki, 00029, Finland
  • Local Institution - 0145
    Tampere, 33521, Finland
  • Local Institution - 0146
    Turku, 20251, Finland
  • Local Institution - 0202
    Brest, Finistère 29609, France
  • Local Institution - 0204
    Créteil, Val-de-Marne 94010, France
  • Local Institution - 0205
    Amiens, 80054, France
  • Local Institution - 0198
    Angers, 49100, France
  • Local Institution - 0101
    Besançon, 25000, France
  • Local Institution - 0217
    Bordeaux, 33076, France
  • Local Institution - 0199
    Clermont-Ferrand, 63000, France
  • Local Institution - 0206
    La Tronche, 38043, France
  • Local Institution - 0075
    Marseille, 13273, France
  • Local Institution - 0200
    Montpellier, 34298, France
  • Local Institution - 0074
    Nice, 06189, France
  • Local Institution - 0163
    Paris, 75014, France
  • Local Institution - 0020
    Pierre Benite Cedax, 69495, France
  • Local Institution - 0188
    Saint-Herblain, 44805, France
  • Local Institution - 0002
    Strasbourg, 67091, France
  • Local Institution - 0003
    Toulouse, 31059, France
  • Local Institution - 0100
    Mainz, Rhineland-Palatinate 55131, Germany
  • Local Institution - 0078
    Aachen, 52074, Germany
  • Local Institution - 0015
    Erfurt, 99028, Germany
  • Local Institution - 0081
    Essen, 45136, Germany
  • Local Institution - 0086
    Frankfurt am Main, 60590, Germany
  • Local Institution - 0080
    Göttingen, 37075, Germany
  • Local Institution - 0013
    Herne, 44625, Germany
  • Local Institution - 0010
    Jena, 07747, Germany
  • Local Institution - 0084
    Lübeck, 23538, Germany
  • Local Institution - 0079
    Magdeburg, 39120, Germany
  • Local Institution - 0082
    München, 81675, Germany
  • Local Institution - 0016
    Nuremberg, 90419, Germany
  • Local Institution - 0085
    Trier, 54292, Germany
  • Local Institution - 0195
    Athens, Attikí 155 62, Greece
  • Local Institution - 0031
    Larissa, Thessalía 411 10, Greece
  • Local Institution - 0194
    Chaïdári, 12462, Greece
  • Local Institution - 0196
    Tel Aviv, Tel Aviv 6423906, Israel

Showing the first 100 of 172 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol Oncol. 2024 Aug;7(4):914-922. doi: 10.1016/j.euo.2023.11.022. Epub 2023 Dec 27. PubMed 38155060 ↗
  • Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, Garzon N, Ibrahim M, Raybold B, Liaw D, Rutstein M, Galsky MD. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. Future Oncol. 2020 Jan;16(2):4359-4368. doi: 10.2217/fon-2019-0611. Epub 2019 Dec 11. PubMed 31823654 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Feb 2026, 87 months.

Of 39 industry-sponsored phase 3 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 74. This study's 87 months is above that.

Counting every sponsor, half of 73 studies reached it within 65 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2018
First posted
Sep 7, 2018
StartActual
Nov 6, 2018
Primary completionActual
Feb 16, 2026
CompletionActual
Apr 14, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03661320
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Nov 6, 2018
Primary completion
Feb 16, 2026
Completion
Apr 14, 2026
Last update
Sep 10, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion